Linear relationships between plasma binding and lipophilicity of disopyramide derivatives

The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs

Quantitative relationships between lipophilicity (characterized by the octanol-water partition coefficient) and binding to both human plasma proteins and blood cells have been studied in a group of model anionic drugs (benzoic and phenylacetic acid derivatives). Protein binding in plasma and accumulation in blood cells in suspension increases with increasing lipophilicity. For quantitative evaluation, the equation log R = a + b log D has been employed, where R is the bound-to-free drug ratio, D is lipophilicity, and a and b are constants. Whereas the protein bound-to-free drug ratio is proportional to drug lipophilicity, the cell bound-to-free drug ratio correlates with lipophilicity to the power 0.685. Distribution in whole blood is affected by protein binding and also by cell accumulation. In blood, the free drug fraction and the fraction in blood cells decrease with increasing lipophilicity, whereas the protein-bound fraction correspondingly increases.

Effects of free fatty acids on the binding of steroid hormones to bovine serum albumin

The effects of binding of free fatty acids (FFA) to bovine serum albumin (BSA) on steroid hormone binding to BSA were examined. The FFA studied included myristic, palmitic, stearic, oleic and linoleic acids. The binding coefficient K was estimated from the changes in the equilibrium partition coefficient between the aqueous and the hexane phase caused by the addition to BSA to the aqueous phase. A noticeable effect of FFA binding (molar ratio FFA/BSA, 2:1) on the affinities of alpha-estradiol, ethynylestradiol and dehydroisoandrosterone to BSA was not observed: however, the affinities of progesterone, androsterone and testosterone were distinctly enhanced by FFA binding. Furthermore, the elution profiles of gel filtration chromatography clearly showed that progesterone and testosterone are easily liberated from the hormone/BSA complexes and that stronger binding of these hormones to BSA is caused by binding of FFA to BSA. The affinity of ethynylestradiol to BSA is stronger than that of progesterone and testosterone and is not affected by palmitic acid binding to BSA.

Plasma protein binding-lipophilicity relationships: interspecies comparison of some organic acids

Relationships between plasma protein binding of 11 organic acids (benzoic and phenylacetic acid derivatives) and their lipophilicity were studied in man, rabbits, rats and mice. For description, the relationship fu = 1/(1 + aDb) was developed, where fu is the fraction of the unbound drug in plasma, D is the partition coefficient octanol/water and a and b are parameters. While the value of the parameter a is widely different in interspecies comparison, the value of the parameter b is very close in all species studied and is approximately equal to 1. The model used allows the simple calculation of the extent of plasma binding of structurally similar drugs from their lipophilicity, or conversion of the extent of plasma binding from one species to another.

Pharmacokinetics of disopyramide in patients with chronic renal failure

The pharmacokinetics study of a single oral dose of 200 mg of disopyramide was performed in 22 normal control subjects and 33 patients with chronic renal failure (CRF). The latter were subdivided into 3 groups of 11 patients each as a function of the gravity of renal insufficiency. With the exception of maximum concentration (C max), which was only slightly modified, and of the apparent distribution volume which remained unchanged, all the other pharmacokinetic blood parameters (t max, concentration at 24th hour, elimination constant (ke h-1), elimination half-life, area under the curve and plasma clearance) were significantly modified in the CRF group; in particular, the elimination half-life was significantly increased (for 22 cases of CRF with mean plasma creatinine greater than 250 microM at 16.3 hours compared to 8.0 hours in controls). The urinary elimination of disopyramide was studied in 14 renal insufficiency patients and in 6 controls. The decreased rate of urinary excretion of disopyramide and its monodealkylated derivative (NMD), during the first 24 hours, was directly related to the severity of renal insufficiency. The ratio of urinary NMD/(disopyramide + NMD) was unchanged in CRF patients as compared to the controls. The results suggest that the dosage of disopyramide should be decreased when plasma creatinine values are greater than 250 microM, and creatinine clearance is less than 30 ml/min. The dose for a 70 kg subject would be 100 mg, administered every 12 hours.

Effect of pKb on lipophilic binding of disopyramide derivatives to human plasma

The extent of plasma binding, the partition coefficient, and the pKb of 13 disopyramide derivatives were determined. The structural variation on the diisopropylaminoethyl group of disopyramide molecules influenced these physical parameters to varying degrees. Results demonstrated that the extent of interaction between drugs and human plasma was a linear function of their lipophilicity and inversely proportional to the magnitude of the pKb value.